2026-08-10 · SEMAGLUTIDE · TopGLP1Providers Data Desk
Oral Wegovy vs the injection: same molecule, new math
The January 2026 launch of the oral Wegovy pill created something this market never had: an FDA-approved GLP-1 at $149–$299 a month cash — below injectable Wegovy’s $349, below most compounded semaglutide programs, and with studied absorption that no compounded sublingual can claim. For the needle-averse, the decision tree collapsed overnight; for everyone else, it reshuffled the whole semaglutide comparison this article walks through.
Updated 2026-08-10 · figures captured 2026-08-09 · how we verify
The three-way price board. Cash, at capture: the oral pill $149–$299 depending on dose via NovoCare↗; injectable Wegovy $349 standard ($199 two-month intro at starter doses); verified compounded injections from $133 (Oak, limited states) and $146 broadly (Yucca Health↗) up through $165 (NexLife↗, dose-flat) and beyond; compounded sublinguals — the pill’s unapproved cousins — at $179–$199, which now means paying more than the approved pill for less evidence, an inversion that ends most of that category’s argument. Annualized, the pill’s low tier runs $1,788 against $4,188 for the injection and $1,752 for the broad compounded floor.
What the pill trades for the price. Oral semaglutide’s absorption chemistry imposes real conditions: daily dosing on an empty stomach with a waiting period before food, versus the injection’s once-weekly set-and-forget; and the injectable retains the larger body of long-term outcome data at the 2.4 mg weekly standard. Dose equivalence is its own conversation — the oral formulations deliver a small absorbed fraction by design, characterized in trials, which is precisely what separates the approved pill from compounded sublinguals that publish no absorption data at all. Whether daily-with-rules beats weekly-with-needles is genuinely personal; what is not personal is that both approved formats now bracket the compounded market’s price range, which changes who should be in that market at all.
Who lands where. Needle-averse and cash-pay: the pill is now the default answer, and anything costing more while proving less carries the burden of proof. Committed to weekly injections with insurance potential: run coverage first (the playbook), then NovoCare’s $349. Cash-pay injectors chasing the floor: the compounded lane still undercuts the injection by $203/month broadly — a gap worth exactly $2,436 a year, weighed against approved-product manufacturing oversight in the full comparison. And anyone whose real question is tirzepatide-versus-semaglutide should settle the molecule before the format: the head-to-head evidence and costs live at that question’s page. Formulation choice, as always, is a prescriber conversation; this page’s job is to make sure you arrive at it holding the right prices.
Dosing conditions summarized from public labeling as general information, not instructions; captured 2026-08-09.